- Home
- INLX vs TPST Comparison
INLX vs TPST Comparison
Compare INLX & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INLX
- TPST
- Stock Information
- Founded
- INLX 1996
- TPST 2011
- Country
- INLX United States
- TPST United States
- Employees
- INLX N/A
- TPST N/A
- Industry
- INLX EDP Services
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- INLX Technology
- TPST Health Care
- Exchange
- INLX Nasdaq
- TPST Nasdaq
- Market Cap
- INLX 40.8M
- TPST 45.5M
- IPO Year
- INLX N/A
- TPST N/A
- Fundamental
- Price
- INLX $11.00
- TPST $10.74
- Analyst Decision
- INLX
- TPST Hold
- Analyst Count
- INLX 0
- TPST 3
- Target Price
- INLX N/A
- TPST $30.00
- AVG Volume (30 Days)
- INLX 6.6K
- TPST 45.5K
- Earning Date
- INLX 11-12-2025
- TPST 11-11-2025
- Dividend Yield
- INLX N/A
- TPST N/A
- EPS Growth
- INLX N/A
- TPST N/A
- EPS
- INLX N/A
- TPST N/A
- Revenue
- INLX $17,127,854.00
- TPST N/A
- Revenue This Year
- INLX N/A
- TPST N/A
- Revenue Next Year
- INLX $14.19
- TPST N/A
- P/E Ratio
- INLX N/A
- TPST N/A
- Revenue Growth
- INLX N/A
- TPST N/A
- 52 Week Low
- INLX $8.74
- TPST $5.35
- 52 Week High
- INLX $16.50
- TPST $20.67
- Technical
- Relative Strength Index (RSI)
- INLX 43.78
- TPST 57.39
- Support Level
- INLX $11.11
- TPST $8.87
- Resistance Level
- INLX $11.55
- TPST $11.07
- Average True Range (ATR)
- INLX 0.12
- TPST 0.50
- MACD
- INLX -0.08
- TPST 0.07
- Stochastic Oscillator
- INLX 21.28
- TPST 83.58
About INLX Intellinetics Inc.
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.